Investigational drug · Phase 2
BIA 28-6156
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Parkinson's Disease.
Phase 2Last checked: Nov 20, 2026Latest source record: Nov 6, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
3
Any phase or sponsor naming "BIA 28-6156"
First trial start
2023
Mar 31, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "BIA 28-6156", any sponsor or status.
Conditions studied
As listed on its trial records.
- Parkinson's Disease
Approved drugs for the same conditions: Parkinson's disease · Neurology
Largest trials
Live from ClinicalTrials.gov: studies naming "BIA 28-6156" as an intervention, largest first.
- Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in GBA-PDPivotal-lookingCompleted
Bial R&D Investments, S.A.Industry
NCT05819359 · 273 participants · Start Mar 31, 2023 · Primary completion Apr 2, 2026
Drug: BIA 28-6156 10 mg; BIA 28-6156 60 mg and 1 more · For: Parkinson's Disease
Sites: Phoenix, Arizona; La Jolla, California; Los Angeles, California · 95 sites in all
Bial R&D Investments, S.A.Industry
NCT05220072 · 6 participants · Start Aug 28, 2021 · Primary completion Oct 16, 2021
Drug: Carbon-14 BIA 28-6156 · For: Parkinson Disease
Sites: Ruddington, United Kingdom
- Compassionate Use for BIA 28-6156 in Patients With Parkinson's Disease (PD) Who Have a Pathogenic Variant in the GBA1 Gene (GBA-PD) and Completed the ACTIVATE StudyNo longer available
Bial R&D Investments, S.A.Industry
NCT07522606
Drug: BIA 28-6156 · For: Parkinson Disease
Sites: Phoenix, Arizona; Aurora, Colorado; Boca Raton, Florida · 36 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- A Randomized, Double-Blinded, Placebo-Controlled QTc Study to Evaluate BIA 28-6156 Effect on Cardiac Repolarization in Healthy Volunteers.
Peixoto I, Hilt D, Carvalho T, et al. · Clin Pharmacol Drug Dev 2026
- A Phase 1B Trial in GBA1-Associated Parkinson's Disease of BIA-28-6156, a Glucocerebrosidase Activator.
den Heijer JM, Kruithof AC, Moerland M, et al. · Mov Disord 2023
Also in development for Parkinson's Disease
- PrasinezumabRO7046015, PRX002Phase 33 trials
Roche (Genentech) · Parkinson's Disease, Parkinsons Disease
- CVN424Phase 32 trials
Cerevance · Parkinson Disease, Parkinson's Disease
- GM1Phase 32 trials
Qilu Pharmaceutical Co., Ltd. · Chemotherapy-induced Peripheral Neuropathy (CIPN), Parkinson's Disease
- iPSChuman allogeneic induced pluripotent stem cell -derived dopaminergic neural progenitor cell, Allogeneic Human Induced Pluripotent Stem Cell -Derived Motor Neuron Progenitor CellsPhase 23 trials
XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd. · Spinal Cord Injury, Safety, Efficacy
- RO7568282Phase 22 trials
Roche (Genentech) · Parkinson's Disease, Alzheimer's Disease
- MT101-5Phase 21 trial
Mthera Pharma Co., Ltd. · Parkinson's Disease
- ND0612ND0612HPhase 21 trial
NeuroDerm Ltd. · Parkinson's Disease
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.